Authors
Qin Xu, Rui Zhu, Zirui Wang, Chengjian Zhao, Xiaofen Li, Nuerye Tuerhong, Wanting Hou, Yu Yang
Published in
Journal of cancer research and clinical oncology. Volume 152. Issue 11. Aug 19, 2026. Epub Aug 19, 2026.
Abstract
Hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM) carries a poor prognosis, and treatment options after failure of anti-angiogenic targeted agents combined with immune checkpoint inhibitor (ICI) remain limited.
An adult patient with advanced HCC exhibited primary resistance to three sequential immunotherapy-based regimens: first-line lenvatinib plus camrelizumab (progressive lung metastases), second-line atezolizumab plus bevacizumab (rapid tumor marker surge), and third-line atezolizumab plus regorafenib (new liver and adrenal metastases within 3 months, suspicious for rapid disease progression following immunotherapy). Fortunately, fourth-line mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and fluorouracil) plus bevacizumab induced a partial response (PR) with significant tumor shrinkage and substantial declines in AFP and PIVKA-II. The case had shown a total progression-free survival (PFS) for more than 21 months until the latest follow-up in June 2026. Then, we performed 24-plex spatial tissue profiling of the primary tumor. The tumor microenvironment revealed three core features: immune-desert (lymphocytes < 5%, no tertiary lymphoid structures, exhausted PD-1 + CD8+ T cells), hyper-vascularization with disorganized endothelium and severe pericyte deficiency (αSMA coverage 2.9%), and high perivascular tumor proliferation.
This unique "immune-desert, vessel-rich, rapidly proliferating" signature potentially accounts for the striking oxaliplatin-based chemotherapy sensitivity despite primary ICI-anti-angiogenic therapy resistance. This case suggests that in selected HCC patients with multiline ICI-anti-angiogenic therapy resistance, prompt transition to chemotherapy plus bevacizumab may yield profound responses.
PMID:
43037761
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0